![Image may contain: .](/cancell/english/news-and-events/news/2020/jacek-otlewski.jpg)
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR-dependent cancers​", with senior scientist Antoni Wiedlocha at CanCell as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish partner, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Wiedlocha has worked on fibroblast growth factor receptors (FGFR) in relation to cancer development a number of years and heads a project group in the Stenmark lab at CanCell and Institute for Cancer Research, Radiumhospitalet.
We congratulate Antoni and his collaborators on obtaining the grant!
More about the award can be found here: